AKESO ADVANCES IO2.0 + ADC2.0 STRATEGY: FIRST PATIENT DOSED IN PHASE II STUDY OF TROP2/NECTIN-4 BISPECIFIC ADC (AK146D1) COMBINED WITH IVONESCIMAB IN BREAST CANCER

Reuters · 3d ago

Please log in to view news